Cortical Spreading Depression (CSD)

What is Cortical spreading depression?

Cortical spreading depression (CSD) is a wave of intense neuronal and glial depolarisation that moves slowly across the cerebral cortex, followed by a prolonged period of reduced electrical activity. First described by Austrian neurologist Aristides Leão in 1944, CSD is not a disease itself but a physiological phenomenon that underlies several neurological conditions, most notably migraine aura. The depolarising wave travels at 2‑5 mm/min, disrupting normal brain metabolism and blood flow, which explains many of the visual and sensory disturbances experienced during an aura.

While CSD is best known for its role in migraine, research shows it also contributes to the progression of brain injuries such as stroke, traumatic brain injury (TBI), and subarachnoid hemorrhage. Understanding CSD helps clinicians predict complications, tailor preventive therapies, and educate patients about triggers.

Common Causes

Although CSD is a physiological response, several conditions increase its likelihood or trigger its onset. The most frequent provocateurs include:

• Migraine with aura – the classic setting where a visual or sensory aura precedes a headache.
<
• Ischemic stroke – the sudden loss of blood supply creates an energy deficit that can initiate CSD.
• Traumatic brain injury (TBI) – mechanical disruption of neural tissue may provoke spreading depolarisation.
• Subarachnoid hemorrhage – blood in the subarachnoid space irritates cortex and can start CSD waves.
• Hemiplegic migraine – a rare migraine variant where CSD spreads to motor cortex, causing temporary weakness.
• Infectious encephalitis – inflammation lowers the threshold for depolarisation.
• Electrolyte disturbances – particularly low magnesium or high calcium, which affect neuronal excitability.
• Pharmacologic triggers – certain drugs (e.g., caffeine, NMDA‑receptor agonists) can lower the threshold.
• Genetic mutations – mutations in CACNA1A, ATP1A2, or SCN1A genes increase susceptibility to CSD.
• Hypoxia – reduced oxygen delivery during high‑altitude exposure or respiratory disease can precipitate spreading depression.

Associated Symptoms

The clinical picture varies with the underlying condition, but the following symptoms frequently accompany CSD:

• Visual aura – scintillating lights, zig‑zag lines, blind spots, or temporary visual loss.
• Somatosensory aura – tingling, numbness, or “pins‑and‑needles” sensations, often starting in the hand and spreading.
• Speech/language disturbances – difficulty finding words or transient aphasia.
• Motor weakness – brief hemiparesis in hemiplegic migraine or after stroke‑related CSD.
• Vertigo or dizziness – especially when CSD spreads to vestibular cortex.
• Headache – typically a throbbing, unilateral pain that follows the aura by 20‑60 minutes.
• Photophobia and phonophobia – increased sensitivity to light and sound.
• Transient loss of consciousness – rare, seen in severe spreading depression after massive brain injury.

When to See a Doctor

Because CSD can signal serious neurological events, prompt medical evaluation is essential if you experience any of the following:

• A sudden, severe headache that peaks within minutes (“thunderclap” headache).
• Aura that lasts longer than 60 minutes or progresses dramatically.
• New weakness, numbness, or difficulty speaking.
• Loss of vision in one eye, or a rapid spread of visual disturbances.
• Symptoms after head trauma, especially if they worsen over hours.
• Fever, neck stiffness, or altered mental status alongside aura.
• Repeated auras that interrupt daily activities or quality of life.

If any of these signs appear, seek emergency care or contact your neurologist as soon as possible.

Diagnosis

Diagnosing CSD involves a combination of clinical assessment, imaging, and, in specialized centers, electrophysiological monitoring.

Clinical History & Physical Exam

• Detailed description of aura (type, duration, spread).
• Headache pattern, triggers, and response to medications.
• Review of risk factors (family history, recent head injury, medication use).

Neuroimaging

• CT scan – fast, rules out acute hemorrhage or stroke.
• MRI with diffusion‑weighted imaging (DWI) – detects early cortical changes linked to spreading depression.
• Perfusion MRI or CT – shows transient hyper‑ or hypoperfusion that accompanies CSD.

Electrophysiology

• Electroencephalography (EEG) – may reveal a slow wave (negative DC shift) during an aura.
• Invasive electrocorticography (ECoG) – used in research or neurosurgical settings to directly record CSD waves.

Laboratory Tests

• Serum electrolytes, magnesium, calcium – to rule out metabolic triggers.
• Genetic testing for CACNA1A, ATP1A2, SCN1A when familial hemiplegic migraine is suspected.

Treatment Options

Therapy focuses on two goals: aborting acute episodes and preventing future CSD‑related events.

Acute Management

• Triptans (e.g., sumatriptan) – effective if taken early during migraine aura; may abort the headache phase.
• NSAIDs (e.g., ibuprofen, naproxen) – help relieve headache pain.
• Intravenous magnesium sulfate – can stabilise neuronal membranes in severe migraine or TBI‑related CSD.
• Oxygen therapy – high‑flow oxygen is useful for cluster‑type headaches that can co‑occur with CSD.
• Antiepileptic drugs (AEDs) such as topiramate or valproate – may reduce aura frequency.

Preventive (Prophylactic) Therapy

• Beta‑blockers (propranolol, metoprolol) – first‑line for migraine prophylaxis.
• Calcium‑channel blockers (verapamil, flunarizine) – especially useful in hemiplegic migraine.
• Antidepressants (amitriptyline, venlafaxine) – assist with chronic migraine and comorbid mood disorders.
• CGRP monoclonal antibodies (erenumab, fremanezumab) – recent trials show reduced aura frequency.
• Lifestyle modifications – trigger avoidance, regular sleep, hydration, and stress management (see Prevention Tips).

Home & Supportive Measures

• Keep a migraine diary to identify personal triggers.
• Apply cold or warm packs to the head/neck during aura.
• Practice relaxation techniques (progressive muscle relaxation, guided imagery).
• Maintain a consistent meal schedule; avoid fasting.
• Limit caffeine to ≤200 mg/day and avoid alcohol during migraine‑prone periods.

Prevention Tips

While CSD cannot always be prevented, many patients reduce its frequency by addressing modifiable factors.

• Identify and avoid triggers – bright lights, strong smells, certain foods (aged cheese, chocolate, MSG), and inadequate sleep.
• Regular sleep hygiene – aim for 7‑9 hours per night, maintain consistent bedtime/wake‑time.
• Stay hydrated – at least 2 L of water daily; dehydration lowers neuronal thresholds.
• Exercise regularly – aerobic activity 3‑5 times per week improves vascular health and reduces migraine attacks.
• Stress management – mindfulness, yoga, or cognitive‑behavioral therapy (CBT) have documented benefits.
• Nutrition – magnesium‑rich foods (leafy greens, nuts, seeds) and riboflavin (vitamin B2) supplementation may lower aura incidence.
• Medication adherence – take prophylactic drugs exactly as prescribed; discuss side‑effects with your physician.
• Monitor hormonal changes – menstrual cycles can influence migraine; discuss hormonal therapy with a gynecologist if needed.
• Regular medical follow‑up – annual neurological review helps adjust treatment plans.

Emergency Warning Signs

Key Take‑aways

Cortical spreading depression is a wave of neuronal depolarisation that underlies migraine aura and contributes to several acute brain injuries. Recognising its hallmark visual and sensory phenomena, understanding the conditions that provoke it, and seeking prompt medical evaluation for warning signs can dramatically improve outcomes. With appropriate acute therapy, preventive medications, and lifestyle changes, most people learn to control aura frequency and reduce its impact on daily life.

References:

• Mayo Clinic. “Migraine with aura.” https://www.mayoclinic.org
• American Heart Association/American Stroke Association. “What is a stroke?” https://www.stroke.org
• National Institute of Neurological Disorders and Stroke (NINDS). “Cortical Spreading Depression.” https://www.ninds.nih.gov
• International Headache Society. “The ICHD‑3 classification of migraine.” https://ichd-3.org
• Cleveland Clinic. “Migraine prevention medications.” https://my.clevelandclinic.org
• World Health Organization. “Headache disorders.” https://www.who.int